WordNet
- a severe or even fatal form of vaccinia that occurs mainly in persons with an immunological deficiency; characterized by progressive enlargement of the initial lesion (同)vaccinia_gangrenosa
- gradually advancing in extent
- a tense of verbs used in describing action that is on-going (同)progressive tense, imperfect, imperfect tense, continuous tense
- favoring or promoting reform (often by government action) (同)reformist, reform-minded
- (of a card game or a dance) involving a series of sections for which the participants successively change place or relative position; "progressive euchre"; "progressive tournaments"
- (of taxes) adjusted so that the rate increases as the amount of income increases
- advancing in severity; "progressive paralysis"
- favoring or promoting progress; "progressive schools"
- a local infection induced in humans by inoculation with the virus causing cowpox in order to confer resistance to smallpox; normally lasts three weeks and leaves a pitted scar (同)vaccina, variola vaccine, variola vaccinia, variola vaccina
PrepTutorEJDIC
- (行列などが)『前進する』,進んで行く / (事態が)進展する,進行する / 『進歩的な』,革新的な / (病気・暴力などが)次第に悪くなる(広がる) / (課税が)累進的な / (文法で)進行[形]の / 進歩的な人,革新主義者
- 牛痘(=cowpox) 痘疹
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/07/24 23:09:35」(JST)
wiki en
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 痘瘡ワクチンとしてのワクシニアウイルス vaccinia virus as the smallpox vaccine
- 2. プリンヌクレオシドホスホリラーゼ欠損症 purine nucleoside phosphorylase deficiency
English Journal
- Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
- Gulley JL1, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.Author information 1Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr., 8B09 MSC 1750, Bethesda, MD 20892, USA. gulleyj@mail.nih.govAbstractThe primary end point of this study was to determine the safety and feasibility of intraprostatic administration of PSA-TRICOM vaccine [encoding transgenes for prostate-specific antigen (PSA) and 3 costimulatory molecules] in patients with locally recurrent or progressive prostate cancer. This trial was a standard 3 + 3 dose escalation with 6 patients each in cohorts 4 and 5 to gather more immunologic data. Nineteen of 21 patients enrolled had locally recurrent prostate cancer after definitive radiation therapy, and 2 had no local therapy. All cohorts received initial subcutaneous vaccination with recombinant vaccinia (rV)-PSA-TRICOM and intraprostatic booster vaccinations with recombinant fowlpox (rF)-PSA-TRICOM. Cohorts 3-5 also received intraprostatic rF-GM-CSF. Cohort 5 received additional subcutaneous boosters with rF-PSA-TRICOM and rF-GM-CSF. Patients had pre- and post-treatment prostate biopsies, and analyses of peripheral and intraprostatic immune cells were performed. There were no dose-limiting toxicities, and the maximum tolerated dose was not reached. The most common grade 2 adverse events were fever (38%) and subcutaneous injection site reactions (33%); the single grade 3 toxicity was transient fever. Overall, 19 of 21 patients on trial had stable (10) or improved (9) PSA values. There was a marked increase in CD4+ (p = 0.0002) and CD8+ (p = 0.0002) tumor infiltrates in post- versus pre-treatment tumor biopsies. Four of 9 patients evaluated had peripheral immune responses to PSA or NGEP. Intraprostatic administration of PSA-TRICOM is safe and feasible and can generate a significant immunologic response. Improved serum PSA kinetics and intense post-vaccination inflammatory infiltrates were seen in the majority of patients. Clinical trials examining clinical end points are warranted.
- Cancer immunology, immunotherapy : CII.Cancer Immunol Immunother.2013 Sep;62(9):1521-31. doi: 10.1007/s00262-013-1448-0. Epub 2013 Jul 9.
- The primary end point of this study was to determine the safety and feasibility of intraprostatic administration of PSA-TRICOM vaccine [encoding transgenes for prostate-specific antigen (PSA) and 3 costimulatory molecules] in patients with locally recurrent or progressive prostate cancer. This trial
- PMID 23836412
- Recombinant DNA vaccine against neurite outgrowth inhibitors attenuates behavioral deficits and decreases Abeta in an Alzheimer's disease mouse model.
- Zhang L1, Ma Q, Yang W, Qi X, Yao Z, Liu Y, Liang L, Wang X, Ma C, Huang L, Xu Y, Zhu H, Deng W, Gao Y, Ruan L, Xiao Z, Qin C.Author information 1Comparative Medicine Center, Peking Union Medical College and Institute of Laboratory Animal Science, Chinese Academy of Medical Science, No 5 Pan Jia Yuan Nan Li, Chaoyang District, Beijing 100021, China.AbstractAlzheimer's disease (AD) is a chronic neurodegenerative disease that causes a progressive loss in learning and memory capabilities and eventually results in dementia. The non-renewable nature of neurons in the central nervous system leads to the basic pathological changes that are related to the various behavioral and psychological symptoms of AD. Oligodendrocyte- and myelin-related neurite outgrowth inhibitors (NOIs) tend to hinder the regeneration of neurons. We designed a recombinant DNA vaccine composed of multiple specific inhibitory domains of NOIs. Vaccination induced effective antibodies against the specific domains in the sera of mice treated with a DNA primed-vaccinia virus boost regimen. The vaccine attenuated neuronal degeneration in the mouse brain and protected the model mice from behavioral deficits. Vaccination also decreased the formation of soluble Aβ oligomer and amyloid plaques in the co-transgenic mice brain. What's more, astrocytosis in brains of APP/PS1 co-transgenic mice was also relieved. The results suggested that immunotherapy with multiple specific domains of myelin- and oligodendrocyte-related NOIs may be a promising approach for Alzheimer's disease and other degenerative central nervous system diseases.
- Neuropharmacology.Neuropharmacology.2013 Jul;70:200-10. doi: 10.1016/j.neuropharm.2012.10.023. Epub 2012 Nov 29.
- Alzheimer's disease (AD) is a chronic neurodegenerative disease that causes a progressive loss in learning and memory capabilities and eventually results in dementia. The non-renewable nature of neurons in the central nervous system leads to the basic pathological changes that are related to the var
- PMID 23201352
- Gene expression in Mammalian cells and its applications.
- Khan KH.Author information School of BioSciences and Technology, VIT University, Vellore-632014, Tamil nadu, India.AbstractThe production of proteins in appropriate quantity and quality is an essential requirement of the present time. There appears to be a progressive increase in the application of mammalian cells for proteins production. Expression systems utilizing mammalian cells for recombinant proteins are able to introduce proper protein folding, post-translational modifications, and product assembly, which are important for complete biological activity. This review article is totally based on literature survey. In this article much emphasis has been done on the mammalian expression system. The author focused on different mammalian cell lines that express the gene. The different vector systems that transfer the gene into mammalian cells like plasmid based expression vectors, adenovirus vectors, vaccinia vectors, retroviral vector and baculovirus as vectors were explored. The processes for the transfer of gene into mammalian cells were also reviewed. Application and limitations of mammalian expression system were also focused. The purpose of research in writing this article is to create awareness in researchers, starting their career in gene expression related to mammalian cells. The principal result and major conclusion of this article is to make available the molecular technologies, expression system and applications of gene expression in mammalian cell lines.
- Advanced pharmaceutical bulletin.Adv Pharm Bull.2013;3(2):257-63. doi: 10.5681/apb.2013.042. Epub 2013 Aug 20.
- The production of proteins in appropriate quantity and quality is an essential requirement of the present time. There appears to be a progressive increase in the application of mammalian cells for proteins production. Expression systems utilizing mammalian cells for recombinant proteins are able to
- PMID 24312845
Japanese Journal
- 慢性リンパ性白血病15症例の臨床的観察:—免疫学的異常を中心に—
- 上平 憲 [他],井上 晃,木下 研一郎,冨安 孝則,玉利 久二男,古賀 庸之,武藤 一巳,市丸 道人
- 臨床血液 15(1), 30-37, 1974
- … L., these cases were divided into four categories: classic type 10 cases, splenomegalic 1 case, specific skin lesions 2 cases, and blood changes-only 2 cases.Several immunological disturbances such as hemolytic anemia with eosinophilia, progressive vaccinia, runting syndrome and various seven infections were recognized. …
- NAID 130004917467
- An autopsy case of progressive vaccinia associated with normal immunoglobulin levels
- Maeda Ryuei [他]
- Acta Pathologica Japonica 20(4), 513-529, 1970-11
- NAID 40018695775
- Progressive Vacciniaについて
- 天谷 博 [他]
- 皮膚科の臨床 4(3), ????, 1962-03
- NAID 40018450811
Related Links
- Progressive vaccinia (vaccinia necrosum), which was fatal, in a child with an immunodeficiency. [from Fenner F., Henderson DA, et al. Smallpox and its Eradication. WHO. 1988]. Reprinted with permission of WHO. Original photo by ...
- Progressive vaccinia is one of the most severe complications of smallpox vaccination. It is almost always life threatening. Progressive vaccinia is the preferred designation for this complication although, in the past, it has ...
Related Pictures
★リンクテーブル★
| リンク元 | 「壊疽性痘疱」「進行性痘疱」 |
| 関連記事 | 「progressive」「vaccinia」 |
「壊疽性痘疱」
「進行性痘疱」
「progressive」
- adj.
- 進行性の